Globalagliatin - Yabao Pharmaceutical
Alternative Names: Globalagliatin hydrochloride; Glubalagliatin; SY-004Latest Information Update: 04 Jan 2023
Price :
$50 *
At a glance
- Originator Yabao Pharmaceutical Group
- Class Antihyperglycaemics
- Mechanism of Action Glucokinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Type 2 diabetes mellitus
Most Recent Events
- 04 Jan 2023 Phase-II development is ongoing in China
- 11 Oct 2021 Suzhou Yabao Pharmaceutical completes a phase I food-drug interaction trial (In healthy volunteers) in China (PO, Capsule) (NCT04907006)
- 31 Aug 2021 Suzhou Yabao Pharmaceutical initiates a phase I food-drug interaction trial (In healthy volunteers) in China (PO, Capsule) (NCT04907006)